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2.71 [CI95%=0.66-12.61], p=0.13). There was no bleeding complication; only 1
STEMI patient died of cardiogenic shock.
Conclusion: In nearly two thirds of STEMI patients, prehospital loading dose of
prasugrel was not efficient at the beginning of pPCI. This “slow responsiveness” has
to be considered to optimize the management of the antiaggregation therapy during
the acute phase, in particular with regard to antiGP2b3a utilization.
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Clinical Outcomes Of Intracoronary Eptifibatide Bolus-only versus
Intracoronary Bolus and Intravenous Infusion of Eptifibatide in Primary
Percutaneous Coronary Intervention
Dinna Kar Nee Soon, Hee Hwa Ho, Kwok Kong Loh, Yau Wei Ooi, David Foo, Paul
Ong, Fahim Jafary
Tan Tock Seng Hospital, Singapore, Singapore
Background: Intracoronary bolus of Eptifibatide during percutaneous coronary
intervention(PCI) for acute myocardial infarction(AMI) has been shown to result in
higher local platelet glycoprotein IIb/IIIa receptor occupancy with improved
microvascular perfusion. We evaluated the safety and efficacy of two regimens of
intracoronary Eptifibatide (bolus-only versus bolus followed by intravenous infusion)
in patients undergoing primary PCI for ST-elevation MI.
Methods: 155 patients(137 male, mean age 55.4±9.2 years)treated with both regimens
were recruited.They were divided into 2 groups: Group A (n=67,43.2%)who received
fixed-dose intracoronary bolus-only(180 μg/kg)Eptifibatide and Group B (n=88,
56.8%) who received intracoronary bolus(180 μg/kg)and continuous intravenous
infusion of Eptifibatide(2 μg/kg/min) for 18 hours.
Results: Both groups had similar baseline clinical characteristics except patients in
Group B had a higher incidence of prior AMI (11.4% vs 1.5% in Group A,
p=0.02).Both groups(> 68%) were equally likely to undergo PCI with implantation of
stents.However, plain old balloon angioplasty was more often performed in Group
B(21.6% vs 6% in Group A, p=0.01). Thrombolysis in Myocardial Infarction (TIMI)
3 flow was achieved in 97% and 92% of patients in Group A and B respectively(p=0.3).
In-hospital mortality was similar in both groups(1.5% in Group A vs 4.5% in Group
B, p=0.4).No significant difference was observed for both groups in terms of target
lesion revascularization and stent thrombosis(0% vs 1.1%, p=NS).There was only one
major bleeding complication with patient from Group A developing a large groin
hematoma post PCI.4 cases and 6 cases of minor bleeding events were observed in
Group A and B respectively(p=NS).
Conclusion: Intracoronary bolus of Eptifibatide with or without continuous
intravenous infusion can be administered safely and effectively for patients undergoing
primary PCI for AMI. Both regimens were associated with good clinical outcomes,
few bleeding events and low in-hospital major adverse cardiac events.
TCT-167
Protease Activated Receptor-1 (PAR-1) Mediated Platelet Aggregation is
Dependant on Clopidogrel Response
Rolf P Kreutz, David A Flockhart, Yvonne Kreutz, Jeffrey A Breall
Cardiology, Indiana University School of Medicine, Indianapolis, IN
Background: Clopidogrel inhibits ADP mediated platelet aggregation (PA) by binding
to the P2Y12 receptor. We hypothesized that clopidogrel-non-response with high
residual PA induced by ADP is associated with high PA induced by PAR-1 stimulation
with thrombin receptor activating peptide (TRAP), when compared to clopidogrel
responders, and that PAR-1 mediated PA is therefore dependant on clopidogrel
response. TRAP induced PA is used in the VerifyNow P2Y12 point-of-care device to
estimate maximal PA on clopidogrel therapy.
Methods: 58 patients undergoing elective PCI were examined with PA measured at
18-24 hours after 600mg clopidogrel loading dose by light transmittance aggregometry.
Agonists used were ADP 5μM, 10μM, 20μM and TRAP at 15μM and 25μM.
Results: Increasing quartiles of 20μM ADP induced PA after clopidogrel loading were
associated with increasing levels of TRAP mediated PA (Graph). Patients in the highest
quartile (clopidogrel non-responders) of post treatment ADP PA had significantly
higher TRAP mediated aggregation than the patients in the lowest quartile (clopidogrel
responders) [TRAP 15 μM: 79.5±1% vs. 69.5±2%, p<0.001].
Conclusion: Non-responders to clopidogrel show high residual PA induced by TRAP,
whereas clopidogrel responders exhibit attenuated response to TRAP. Methods using
TRAP stimulated maximal aggregation as baseline to calculate percent platelet
inhibition by clopidogrel may thus underestimate the degree of inhibition in clopidogrel
responders. Addition of PAR-1 antiplatelet drugs may be most effective in patients
with reduced clopidogrel response and high TRAP mediated PA.
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Adherence to Evidence-Based Medical Therapy According to Management
Strategy in Patients With Acute Coronary Syndrome
Samer Mansour, Riahi Mounir, Louis-Mathieu Stevens, Nicolas Noiseux, Andre
Kokis, Francois Gobeil
Centre hospitalier de l’Universite de Montreal, Montreal, Canada
Background: Despite evidence supporting the pharmacological treatment in acute
coronary syndrome (ACS), several registries suggested lack of adherence to guidelines.
We aim to evaluate the adoption of the evidence-based medical therapy (EBM) in the
clinical practice in patients with ACS stratified according to the management strategy.
Methods: We conducted a retrospective analysis on 176 consecutive patients admitted
for ACS. We examined the discharge prescription of EBM defined as the combination
of anti-platelets, β-blockers (BB), angiotensin pathway inhibitors (ACEI/ARB) and
lipid-lowering therapy. Study population was stratified according to medical therapy
alone, percutaneous coronary intervention (PCI) or surgical revascularisation
Results: Patients mean age was 66±12 years, 24% were females and 31% had diabetes.
Patients were admitted for unstable angina in 27%, non-ST-elevation myocardial
infarction (MI) 46% and ST-elevation MI 27% of cases. Coronary angiogram was
performed in 90%. Medical therapy was allocated for 26% (cohort A), PCI for 50%
(Cohort B) and surgery for 24% of patients (Cohort C). No significant difference was
noted between the cohorts regarding to age, gender, diabetes, and LVEF. However, in
the cohort A as compared to B and C, patients had a higher rate of hypertension (85%
vs. 51% vs. 62% respectively, p=0.002), known coronary artery disease (71% vs. 43%
vs. 31% respectively, p <0.001) and higher creatinin level (mmol/dl) (148±96 vs.
105±67 vs. 112±88 respectively, p= 0.033). No significant difference was noted
between the cohorts A, B and C regarding the treatment with B-blockers (97% vs. 86%
vs. 84% respectively, p=0.139) and lipid lowering treatment (91% vs. 94% vs. 92%
respectively, p= 0.804). However, lower rate of aspirin prescription was noted in the
cohort A as compared to the cohort B and C (79%, 95% vs. 97%, respectively, p=
0.010) and lower rate of angiotensin pathway inhibitors in the cohort C as compared
to the cohort A and B (31% vs. 59% vs. 69% respectively, p<0.001). Finally high rate
of clopidogrel was only noted in the cohort B as compared to the cohort A and C (94%
vs. 29% vs. 7% respectively, p< 0.001)
Conclusion: In the setting of ACS management, higher rate of adoption to EBM was
noted in PCI treated patients. There is room for improvement mainly when patients
are treated with medical therapy or surgical revascularization.
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